CO2022012062A2 - Anticuerpos contra klk5 - Google Patents
Anticuerpos contra klk5Info
- Publication number
- CO2022012062A2 CO2022012062A2 CONC2022/0012062A CO2022012062A CO2022012062A2 CO 2022012062 A2 CO2022012062 A2 CO 2022012062A2 CO 2022012062 A CO2022012062 A CO 2022012062A CO 2022012062 A2 CO2022012062 A2 CO 2022012062A2
- Authority
- CO
- Colombia
- Prior art keywords
- klk5
- antibodies against
- antibodies
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La presente invención se refiere a anticuerpos que se unen a, e inhiben, KLK5 y a métodos de uso de los mismos para tratar enfermedades provocadas por un desequilibrio de KLK5. En particular, la presente invención se refiere a anticuerpos anti-KLK5 inhibidores y a su uso en el tratamiento de enfermedad de Netherton, dermatitis atópica y cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2001447.8A GB202001447D0 (en) | 2020-02-03 | 2020-02-03 | Antibodies |
| PCT/EP2021/052249 WO2021156171A1 (en) | 2020-02-03 | 2021-02-01 | Antibodies against klk5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022012062A2 true CO2022012062A2 (es) | 2022-08-30 |
Family
ID=69800047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0012061A CO2022012061A2 (es) | 2020-02-03 | 2022-08-24 | Anticuerpos contra klk5 |
| CONC2022/0012062A CO2022012062A2 (es) | 2020-02-03 | 2022-08-24 | Anticuerpos contra klk5 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0012061A CO2022012061A2 (es) | 2020-02-03 | 2022-08-24 | Anticuerpos contra klk5 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20230075753A1 (es) |
| EP (2) | EP4100441A1 (es) |
| JP (2) | JP2023512320A (es) |
| KR (2) | KR20220137669A (es) |
| CN (2) | CN115038722A (es) |
| AR (2) | AR121254A1 (es) |
| AU (2) | AU2021216646A1 (es) |
| BR (2) | BR112022015281A2 (es) |
| CA (2) | CA3169838A1 (es) |
| CL (2) | CL2022002078A1 (es) |
| CO (2) | CO2022012061A2 (es) |
| EC (2) | ECSP22060844A (es) |
| GB (2) | GB202001447D0 (es) |
| IL (2) | IL295248A (es) |
| MX (2) | MX2022009474A (es) |
| PE (2) | PE20221921A1 (es) |
| TW (2) | TW202134276A (es) |
| WO (2) | WO2021156171A1 (es) |
| ZA (2) | ZA202208589B (es) |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| DE69922159T2 (de) | 1998-01-23 | 2005-12-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Mehrzweck-antikörperderivate |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| ES2374068T3 (es) | 2002-12-03 | 2012-02-13 | Ucb Pharma, S.A. | Ensayo para identificar células productoras de anticuerpos. |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| PT1644412E (pt) | 2003-07-01 | 2015-12-23 | Ucb Biopharma Sprl | Fragmentos de anticorpos fab modificados |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| PL2334705T3 (pl) | 2008-09-26 | 2017-06-30 | Ucb Biopharma Sprl | Produkty biologiczne |
| ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB0920324D0 (en) | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| CN103097417B (zh) | 2010-04-20 | 2019-04-09 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| PL2776466T3 (pl) | 2011-11-11 | 2018-01-31 | Ucb Biopharma Sprl | Przeciwciała wiążące albuminę i ich fragmenty wiążące |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201411420D0 (en) | 2014-06-26 | 2014-08-13 | Ucb Biopharma Sprl | Antibody constructs |
| US20200040103A1 (en) * | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
| GB201811368D0 (en) | 2018-07-11 | 2018-08-29 | Ucb Biopharma Sprl | Antibody |
-
2020
- 2020-02-03 GB GBGB2001447.8A patent/GB202001447D0/en not_active Ceased
- 2020-05-28 GB GBGB2008022.2A patent/GB202008022D0/en not_active Ceased
-
2021
- 2021-02-01 WO PCT/EP2021/052249 patent/WO2021156171A1/en active Application Filing
- 2021-02-01 WO PCT/EP2021/052245 patent/WO2021156170A1/en active Application Filing
- 2021-02-01 AU AU2021216646A patent/AU2021216646A1/en active Pending
- 2021-02-01 CA CA3169838A patent/CA3169838A1/en active Pending
- 2021-02-01 US US17/759,986 patent/US20230075753A1/en active Pending
- 2021-02-01 PE PE2022001521A patent/PE20221921A1/es unknown
- 2021-02-01 EP EP21702978.4A patent/EP4100441A1/en active Pending
- 2021-02-01 CN CN202180012224.2A patent/CN115038722A/zh active Pending
- 2021-02-01 KR KR1020227028758A patent/KR20220137669A/ko unknown
- 2021-02-01 CN CN202180012280.6A patent/CN115052900A/zh active Pending
- 2021-02-01 AU AU2021217523A patent/AU2021217523A1/en active Pending
- 2021-02-01 MX MX2022009474A patent/MX2022009474A/es unknown
- 2021-02-01 BR BR112022015281A patent/BR112022015281A2/pt not_active Application Discontinuation
- 2021-02-01 IL IL295248A patent/IL295248A/en unknown
- 2021-02-01 KR KR1020227028757A patent/KR20220137668A/ko unknown
- 2021-02-01 EP EP21702982.6A patent/EP4100442A1/en active Pending
- 2021-02-01 US US17/759,988 patent/US20230070261A1/en active Pending
- 2021-02-01 JP JP2022547167A patent/JP2023512320A/ja active Pending
- 2021-02-01 JP JP2022547072A patent/JP2023512304A/ja active Pending
- 2021-02-01 PE PE2022001522A patent/PE20221922A1/es unknown
- 2021-02-01 CA CA3169842A patent/CA3169842A1/en active Pending
- 2021-02-01 BR BR112022015279A patent/BR112022015279A2/pt unknown
- 2021-02-01 MX MX2022009475A patent/MX2022009475A/es unknown
- 2021-02-01 IL IL295247A patent/IL295247A/en unknown
- 2021-02-03 AR ARP210100276A patent/AR121254A1/es unknown
- 2021-02-03 TW TW110104070A patent/TW202134276A/zh unknown
- 2021-02-03 AR ARP210100277A patent/AR121255A1/es unknown
- 2021-02-03 TW TW110104069A patent/TW202140569A/zh unknown
-
2022
- 2022-08-01 ZA ZA2022/08589A patent/ZA202208589B/en unknown
- 2022-08-01 ZA ZA2022/08588A patent/ZA202208588B/en unknown
- 2022-08-02 CL CL2022002078A patent/CL2022002078A1/es unknown
- 2022-08-02 CL CL2022002079A patent/CL2022002079A1/es unknown
- 2022-08-03 EC ECSENADI202260844A patent/ECSP22060844A/es unknown
- 2022-08-03 EC ECSENADI202260834A patent/ECSP22060834A/es unknown
- 2022-08-24 CO CONC2022/0012061A patent/CO2022012061A2/es unknown
- 2022-08-24 CO CONC2022/0012062A patent/CO2022012062A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| PA8849001A1 (es) | Anticuerpos de c-met | |
| CL2019000935A1 (es) | Composición farmacéutica, métodos para tratamiento y usos de la misma. | |
| CR20170014A (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
| CL2020002446A1 (es) | Anticuerpos contra mica y/o micb y sus usos | |
| AR109948A1 (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| ECSP20063690A (es) | Anticuerpos | |
| CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| CL2019003670A1 (es) | Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta. | |
| AR115288A1 (es) | Anticuerpos humanizados contra el psma | |
| CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
| ECSP22066085A (es) | ANTICUERPOS CONTRA LA INTEGRINA alfaVß8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL | |
| AR081321A1 (es) | N-cadherina: un blanco para el diagnostico y la terapia del cancer | |
| DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp | |
| CO2022012061A2 (es) | Anticuerpos contra klk5 | |
| CL2020000127A1 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa. | |
| CO2022014199A2 (es) | Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus, incluyendo covid-19 | |
| CO2024001711A2 (es) | Anticuerpos anti hla-g | |
| AR117405A1 (es) | Uso de conjugados anticuerpo-fármaco que comprenden agentes que alteran la tubulina para tratar tumores sólidos | |
| CO2022003324A2 (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares | |
| ECSP22020678A (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares | |
| ECSP21075150A (es) | Complejo cosmético y usos del mismo |